{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39","upperLimit":"60","value":"49"},{"groupId":"OG001","lowerLimit":"28","upperLimit":"49","value":"38"},{"groupId":"OG002","lowerLimit":"18","upperLimit":"37","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"92"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"A response is any of complete hematological remission, partial remission, or hematologic improvement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nLenalidomide: Given PO","id":"OG000","title":"Arm 1: Azacitidine/Lenalidomide"},{"description":"Patients receive azacitidine as in Arm 1. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV","id":"OG001","title":"Arm 2: Azacitidine"},{"description":"Patients receive azacitidine as in Arm 1 and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nVorinostat: Given PO","id":"OG002","title":"Arm 3: Azacitidine/Vorinostat"}],"paramType":"NUMBER","populationDescription":"Analysis includes eligible patients only.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Response Rate (Phase II)","type":"PRIMARY","unitOfMeasure":"percentage of patients having a response"}